VivoSeq
Infectious Disease

Respiratory Syncytial Virus Infections

5

Pipeline Programs↗

4

Active Trials↗

5

Companies Involved↗

Respiratory Syncytial Virus Infections is an early-stage landscape with 5 programs across 5 companies. The most active players are Shionogi, Eli Lilly, Shanghai Ark Biopharmaceutical Co., Ltd.. 2 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

31/100

Pipeline Velocity

15/100

Mech. Concentration

N/A

Completion Rate

50/100

Attrition Rate

17/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Shionogi logo

Shionogi

1 program

Phase 2Eli Lilly logo

Eli Lilly

1 program

Phase 2S

Shanghai Ark Biopharmaceutical Co., Ltd.

2 programs

Phase 2GSK logo

GSK

1 program

Phase 3Pfizer logo

Pfizer

0 programs

Preclinical

Pipeline

Programs by Phase

Analysis

Modality Breakdown

80%

Small molecule

4 of 5 classified programs — the dominant modality here.

20%ALL OTHERSVaccine120%

Small molecule leads; the ring shows all 5 classified programs, each share of the total. Modality classified for 71% of 7 pipeline programs.

Analysis

Trial Status

6

clinical trials

Recruiting3 · 50%
Not yet recruiting1 · 17%
Completed1 · 17%
Terminated1 · 17%

Clinical Trials

Trial Activity

6 trials

A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Safety, Tolerability, and Efficacy of S-337395 in Symptomatic Nonhospitalized Adults With Respiratory Syncytial Virus Who Are at High Risk of Progression to Severe Disease
Recruiting·Shionogi logoShionogi·Phase 2·NCT07214571·192 enrolled
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Safety and Efficacy of Human Interferon α1b Inhaled Solution in the Treatment of Respiratory Syncytial Virus Lower Respiratory Tract Infection in Children.
Recruiting·KKexing Biopharm Co., Ltd.·Phase 3·NCT06363370·322 enrolled
A Randomized, Double-blind, Two-stage, Placebo-controlled Phase 2b/3 Clinical Study to Evaluate the Efficacy and Safety of Ziresovir (AK0529) in Adult Patients at High Risk for Respiratory Syncytial Virus (RSV) Infection.
Recruiting·SShanghai Ark Biopharmaceutical Co., Ltd.·Preclinical·NCT07658534·290 enrolled
Evaluating the Benefits Of RSV MaternaL vAccination Using a Scottish National Dataset.
Not yet recruiting·Pfizer logoPfizer·N/A·NCT07235397·1 enrolled
A Phase 3, Randomized, Placebo-controlled, Observer-blind Study in India to Evaluate Immune Response, Reactogenicity and Safety of a Single Intramuscular Dose of RSVPreF3 OA Investigational Vaccine When Administered to Older Adults >=60 Years of Age and Adults 50-59 Years of Age at Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease
Completed·GSK logoGSK·Phase 3·NCT06614725·751 enrolled
A Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Orally Administered AK0529 in Adults With Respiratory Syncytial Virus Infection
Terminated·SShanghai Ark Biopharmaceutical Co., Ltd.·Phase 2·NCT03699202·1 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)